TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30220261
Drug: Present-Centered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-Centered Therapy (PCT; 10 sessions over 8 weeks)
Study: 26289619
Drug: Avenanthramides (AVA)
Normalized name: AVENANTHRAMIDES
DrugBank: Avenanthramides (DB14743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenanthramides (AVA) supplementation (9.2 mg AVA per day)
Study: 24645793
Drug: Control (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.4 mg AVA per day)
Study: 22002961
Drug: Gaboxadol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol (15 mg for subjects <65 years and 10 mg for subjects ≥65 years)
Study: 16446317
Drug: Cyclic schedule
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic schedule of ProMECE-CytaBOM chemotherapy (cyc-PC, 6 cycles)
Study: 16446317
Drug: Modified version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified version of ProMECE-CytaBOM chemotherapy (seq-PC)
Study: 28327266
Drug: Xylitol (8g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (8g per 200 mL milk once per day)
Study: 28327266
Drug: Xylitol (4g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (4g per 100 mL milk twice per day)
Study: 28327266
Drug: Sorbitol (8g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (8g per 200 mL milk once per day)
Study: 28327266
Drug: Sorbitol (4g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (4g per 100 mL milk twice per day)
Study: 28327266
Drug: Sucrose (8g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (8g per 200 mL milk once per day)
Study: 28327266
Drug: Xylitol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (twice per day)
Study: 28327266
Drug: Sorbitol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (twice per day)
Study: 19171274
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (group 2)
Study: 11788637
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg T enanthate
Study: 11788637
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg T enanthate
Study: 11719309
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg/d for Week 1; 400 mg/d for Weeks 2 to 4)
Study: 9387176
Drug: Pressure-ridge Molteno
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-ridge Molteno implant
Study: 9387176
Drug: Standard Molteno
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Molteno implant with suture ligation
Study: 9387176
Drug: Suture-ligation implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture-ligation implant group
Study: 9387176
Drug: Pressure-ridge implant
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-ridge implant group
Study: 7935033
Drug: 0.6 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/day of conjugated equine oestrogen (CEE) cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Study: 7935033
Drug: 50 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/day of transdermal oestradiol cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Study: 7935033
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day of CEE + 5 mg/day of MPA uninterruptedly
Study: 1587378
Drug: Treatment-free control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free control group
Study: 31803089
Drug: Bergen 4-day
Normalized name: LACTOBACILLUS BREVIS (ORLA-JENSEN, 1919) BERGEY ET AL., 1934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergen 4-day treatment (B4DT)
Study: 29952241
Drug: Vibration stimulus
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration stimulus (n = 14), low-frequency and low-magnitude (27-32 Hz, 0.3 g), 20 minutes, 3 times per week for 12 weeks
Study: 27157469
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g soy protein isolate (SP20)
Study: 27157469
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g soy protein isolate (SP40)
Study: 27157469
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g soy protein isolate (SP0)
Study: 10928300
Drug: Conventional agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional agents and calcium channel blockers
Study: 6753245
Drug: Misonidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (400 mg/m2) administered with each of the 30 fractions of radiotherapy
Study: 6753245
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered with each of the 30 fractions of radiotherapy
Study: 28912639
Drug: Levobupivacaine only
Normalized name: Levobupivacaine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine only (0.5%) 0.4 mg·kg‐1
Study: 28912639
Drug: Levobupivacaine (0.5%)
Normalized name: levobupivacaine 0.5 MG/ML
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine (0.5%) 0.4 mg·kg‐1 + adrenaline (1:200,000)
Study: 21610205
Drug: Gastric-retentive extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-retentive extended-release (ER) formulation (4 hours)
Study: 21610205
Drug: Gastric-retentive extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-retentive extended-release (ER) formulation (6 hours)
Study: 21610205
Drug: M-ER (comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-ER (comparator ER tablet)
Study: 17457961
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg GBE complexed with phosphatidylserine
Study: 17457961
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg GBE complexed with phosphatidylcholine
Study: 17457961
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg GBE
Study: 16449074
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy plus one Botulinum Toxin A injection
Study: 14501381
Drug: Selenized yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenized yeast (both doses)
Study: 10323688
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of sulbactam‐ampicillin combination
Study: 1930858
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 to 40 mg/day for 8 weeks)
Study: 1930858
Drug: Captopril (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5 to 75 mg/day for 8 weeks)
Study: 7172738
Drug: Lotion V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lotion V
Study: 7172738
Drug: Lotion K
Normalized name: SA 6% Lotion Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion K
Study: 21635709
Drug: Tamoxifen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (5 years monotherapy)
Study: 21635709
Drug: Letrozole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5 years monotherapy)
Study: 11392406
Drug: Levodopa-carbidopa suspension
Normalized name: carbidopa / levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa-carbidopa suspension in Ora Plus/Ora Sweet
Study: 11392406
Drug: Levodopa-carbidopa suspension
Normalized name: carbidopa / levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa-carbidopa suspension with ascorbic acid
Study: 11392406
Drug: Levodopa-carbidopa suspension
Normalized name: carbidopa / levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa-carbidopa suspension
Study: 1846438
Drug: Continuous schedule
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous schedule (daily estrogen and progestin)
Study: 1846438
Drug: Sequential schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential schedule (conjugated estrogen on days 1‐25, medroxyprogesterone acetate on days 16‐25)
Study: 6356630
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid (daily dose 600 mg)
Study: 6356630
Drug: ibuprofen (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen (daily dose 1200 mg)
Study: 22708417
Drug: Standard pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacotherapy
Study: 25719617
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (imipramine 75 mg/d + pregabalin 300 mg/d)
Study: 25719617
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg/d)
Study: 25719617
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 mg/d)
Study: 24733680
Drug: Weekly problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly problem-solving group intervention
Study: 22282884
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 mL daily for 10 days)
Study: 22282884
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution, intravenous infusion for 10 days)
Study: 15626943
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (HBV) plus measles vaccine
Study: 15626943
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine only
Study: 15626943
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (HBV)
Study: 27265388
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (>85% cocoa), 40 g/day for 2 weeks
Study: 27265388
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (<35% cocoa), 40 g/day for 2 weeks
Study: 24518826
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg⁻¹ body mass)
Study: 20300126
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment group (21 patients)
Study: 18836927
Drug: Psychotherapeutic day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic day treatment programme (5 months duration, including psychodynamic and cognitive-based therapy in group/individual settings)
Study: 16651155
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with propofol infusion (LAP)
Study: 9335416
Drug: Losartan (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (combined with ACE inhibitor)
Study: 3021083
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride (alpha 2‐adrenergic receptor agonist)
Study: 3021083
Drug: Yohimbine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha 2‐adrenergic receptor antagonist)
Study: 30665850
Drug: Continuous bilateral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bilateral ESPB (0.25 mL/kg/side of ropivacaine 0.5%)
Study: 30665850
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IV morphine, 0.5 mg/h and IV nefopam, 100 mg/24 h)
Study: 27699819
Drug: PSA growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA growth curve model with a threshold of 0.37 ng/ml/year
Study: 27699819
Drug: PSA growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA growth curve model with a threshold of 0.99 ng/ml/year in African-American men (AA)
Study: 19172243
Drug: Trientine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trientine (600 mg orally twice daily)
Study: 7755459
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (quinapril 20 mg)
Study: 797547
Drug: Halcinonide cream
Normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide cream
Study: 1094960
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate cream
Study: 26500862
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB (NBUVB) phototherapy at a fixed dose of 250 mJ/cm² three times a week for 4 weeks
Study: 16669305
Drug: Weekly ultrasound
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly ultrasound combined with standard care
Study: 15606390
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (5‐aminlevulinic acid 30 mg/kg and red light)
Study: 15606390
Drug: Argon plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon plasma coagulation (administered at a power setting of 65 W)
Study: 8742796
Drug: DMT (naturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT (naturally occurring short‐acting hallucinogen), dosage and duration not specified
Study: 31992604
Drug: Telehealthcare solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealthcare solution (Telekit with tablet, digital blood pressure monitor, and scale)
Study: 31992604
Drug: Telehealthcare solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealthcare solution
Study: 25729661
Drug: BoNT‐A (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A (40 Ipsen units per injection)
Study: 18155484
Drug: Buccal infiltrations
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltrations (BI) with 1.7 mL of 4% articaine with 1:100,000 adrenaline
Study: 11353990
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 800 mg/day with interferon
Study: 7761010
Drug: Buprenorphine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.01 mg/kg) with a primer of 0.003 mg/kg of buprenorphine
Study: 7761010
Drug: Buprenorphine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.01 mg/kg) with a primer of 0.5 mg/kg of ketorolac
Study: 3186087
Drug: Intrapartum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum treatment with ampicillin and gentamicin during labor
Study: 3186087
Drug: Postpartum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum treatment
Study: 31448420
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen low dose
Study: 31448420
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen high dose
Study: 29969928
Drug: Tiotropium as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium as add-on therapy to inhaled corticosteroids
Study: 29969928
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting beta agonist as add-on therapy to inhaled corticosteroids
Study: 25275069
Drug: Daily erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily erlotinib for 12 consecutive days prior to docetaxel (Arm A)
Study: 25275069
Drug: Docetaxel followed
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel followed by daily erlotinib (Arm B)
Study: 17488457
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose clamped at 5 mmol/l
Study: 17488457
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose clamped at 15 mmol/l
Study: 15337134
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 500 mg b.d., titrated to a maximum of 3 g/day
Study: 8903618
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors monotherapy
Study: 11527126
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg o.d.
Study: 3319646
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg o.d.
Study: 28067701
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (control)
Study: 23407853
Drug: Sitagliptin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin monotherapy (100 mg)
Study: 23407853
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg for 5 days) + Sitagliptin (100 mg on day 5)
Study: 15565033
Drug: 5-mL vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mL vacuum collection tubes
Study: 15565033
Drug: 10-mL vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mL vacuum collection tubes
Study: 11487548
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/d for 1 week
Study: 7625469
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 80 mg/day)
Study: 26645407
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) trastuzumab 600 mg
Study: 26645407
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) trastuzumab (weight-based)
Study: 19134350
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (puberty gingivitis)
Study: 12876091
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg three times a day
Study: 9097988
Drug: Mesalamine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (750 mg four times a day for 48 weeks)
Study: 17907289
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin, 5-FU, and enteric-coated tegafur/uracil
Study: 10212791
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy
Study: 15167313
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (while continuing 2.5 mg of oral medroxyprogesterone acetate)
Study: 15167313
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Study: 11181465
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d for 3 months
Study: 3326743
Drug: 3 Lf
Normalized name: HYDROXYPROPYL CELLULOSE LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Lf diphtheria vaccine
Study: 3326743
Drug: 7.5 Lf
Normalized name: Diphtheria Toxoid, Adsorbed/Pertussis Vaccine, Acellular/Tetanus Toxoid 7.5 LF U/0.5 ML-300 HA U/0.5 ML-5 LF U/0.5 ML Intramuscular Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 Lf diphtheria vaccine
Study: 29268022
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into the rotator interval (RI)
Study: 29268022
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into the intra-articular (IA) space
Study: 29268022
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into the subacromial (SA) space
Study: 28577840
Drug: WATCHMAN implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: WATCHMAN implant
Study: 11145281
Drug: PPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI treatment
Study: 17373915
Drug: Rifaximin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1200 mg/day)
Study: 3669757
Drug: Lymphoblastoid alpha-interferon
Normalized name: interferon alfa-n1 lymphoblastoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid alpha-interferon (3 mega units daily subcutaneously until complete or partial response)
Study: 29565302
Drug: Daily group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily group hygiene activities
Study: 27837658
Drug: OLZ +
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OLZ + ZIP (combination therapy)
Study: 27837658
Drug: ZIP (ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZIP (ziprasidone monotherapy)
Study: 25424689
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg plus lercanidipine 5 mg (Group A)
Study: 25424689
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg (Group B)
Study: 25424689
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg (Group C)
Study: 23932463
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg/d
Study: 11348939
Drug: SR bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR bupropion treatment (100, 150, or 300 mg/d) for 7 weeks